How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu; Filippo De Braud; Giuseppe Lo Russo; Laura Concas; Daniela Femia; Claudio Vernieri; Alice Indini; Barbara Formisano; Roberto Buzzoni

doi:10.18632/oncotarget.8601

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu _, Filippo De Braud, Giuseppe Lo Russo, Laura Concas, Daniela Femia, Claudio Vernieri, Alice Indini, Barbara Formisano and Roberto Buzzoni

PDF | HTML | How to cite

Oncotarget. 2016; 7:44841-44847. https://doi.org/10.18632/oncotarget.8601

Metrics: PDF 2699 views | HTML 2431 views | ?

Abstract

Sara Pusceddu1,2, Filippo De Braud1,2, Giuseppe Lo Russo1,2, Laura Concas1,2, Daniela Femia1,2, Claudio Vernieri1,2, Alice Indini1,2, Barbara Formisano1,2 and Roberto Buzzoni1,2

1 Medical Oncology Department, ENETs Center of Excellence, Milan, Italy

2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Correspondence to:

Sara Pusceddu, email:

Keywords: everolimus, neuroendocrine tumors

Received: December 14, 2015 Accepted: March 10, 2016 Published: April 05, 2016

Abstract

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.

In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8601

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Abstract